Troy Sukhu, MD
Urology · Annapolis, MDNPI 1508276734
Payments from drug & device makers
Across 160 payments — averaging $69.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Boston Scientific$2K
- Astellas Pharma US Inc$787
- Neotract Inc.$778
- Sumitomo Pharma America, Inc.$355
- Dendreon Pharmaceuticals LLC$292
- plus $3K from 34 others
What the payments were for
- Consulting fees$3,54532%
- Travel & lodging$1,50413%
- Food & beverage$6,14255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $4,181 |
| Boston Scientific | 24 | $1,558 |
| Astellas Pharma US Inc | 12 | $787 |
| Neotract Inc. | 7 | $778 |
| Sumitomo Pharma America, Inc. | 19 | $355 |
| Dendreon Pharmaceuticals LLC | 4 | $292 |
| Bard Access Systems, Inc. | 1 | $275 |
| Dornier Medtech America, Inc | 1 | $259 |
| Urovant Sciences Inc | 6 | $254 |
| Endo USA, Inc. | 7 | $242 |
| Telix Pharmaceuticals | 4 | $232 |
| Baxter Healthcare | 2 | $231 |
| Ferring Pharmaceuticals Inc. | 9 | $218 |
| Urogen Pharma, Inc. | 6 | $208 |
| Teleflex LLC | 4 | $182 |
| Conmed Corporation | 3 | $139 |
| Immunitybio, Inc. | 3 | $132 |
| Tolmar, Inc. | 5 | $109 |
| AbbVie | 5 | $109 |
| Bayer | 3 | $77 |
| Coloplast | 1 | $68 |
| Philips North America LLC | 1 | $50 |
| Innovation Technologies Inc | 1 | $48 |
| Olympus America Inc. | 2 | $46 |
| Myovant Sciences Inc. | 1 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Antares Pharma, Inc. | 2 | $36 |
| Axonics, Inc. | 1 | $26 |
| 180 Medical, Inc. | 1 | $25 |
| Accord Healthcare, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Medtronic | 1 | $18 |
| Merck | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Calyxo, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Sagent Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$3,953
- UroLift$555
- AMS 700$429
- XTANDI$393
- GENERAL ERECTILE DYSFUNCTION$338
- Dornier MedTech$259
- PROVENGE$251
- ILLUCCIX$235
- GEMTESA$208
- PerClot$137
- UroLift System$133
- AMS$119
- XIAFLEX$113
- AIRSEAL$104
How this compares
$11,191 in reported general payments places this provider in the 70th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 24 | $28,970 |
| MyrbetriqMirabegron | 24 | $20,998 |
| Tamsulosin Hcl | 203 | $3,994 |
| Silodosin | 54 | $3,905 |
| Desmopressin Acetate | 12 | $1,407 |
| Solifenacin Succinate | 32 | $1,396 |
| Estradiol | 17 | $1,190 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $961 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $657 |
| Finasteride | 37 | $638 |
| Cefdinir | 40 | $535 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $164 |
| Ciprofloxacin Hcl | 20 | $77 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $71 |
| Oxycodone Hcl | 18 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $355 | $28,97024 claims |
| Astellas Pharma US IncMyrbetriq | $787 | $20,99824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 274 urology providers in Maryland.
Other urology in Annapolis
- Richard LevinAnnapolis$453K
- Juddson ChasonAnnapolis$20K
- David McDermottAnnapolis$19K
- Shaoqing ZhouAnnapolis$15K
- James MastersonAnnapolis$14K
- Mara HoltonAnnapolis$13K
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.